Anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in people with myasthenia gravis

Lire cet article en français

Takeaway

  • The prevalence of low-density-lipoprotein-receptor-associated protein 4 (LRP4) autoantibodies is higher in children and females with myasthenia gravis, with clinical manifestations often involving ocular and limb muscles.

Why this matters

  • LRP4 antibodies have recently been identified in people with myasthenia gravis (MG), however, the clinical features have not been previously described.

  • Further understanding of the different serological sub-types will help to predict disease severity and prognosis and will guide treatment strategies in people with MG.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.